002898 Stock Overview
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sailong Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.26 |
| 52 Week High | CN¥15.37 |
| 52 Week Low | CN¥7.70 |
| Beta | 0.13 |
| 11 Month Change | 5.43% |
| 3 Month Change | 29.87% |
| 1 Year Change | -25.48% |
| 33 Year Change | 13.62% |
| 5 Year Change | -2.40% |
| Change since IPO | 3.48% |
Recent News & Updates
Recent updates
Some Shareholders Feeling Restless Over Sailong Pharmaceutical Group Co.,Ltd.'s (SZSE:002898) P/S Ratio
Oct 01
Impressive Earnings May Not Tell The Whole Story For Sailong Pharmaceutical GroupLtd (SZSE:002898)
Apr 26Subdued Growth No Barrier To Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) With Shares Advancing 27%
Mar 08Shareholder Returns
| 002898 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.2% | -1.3% | -3.4% |
| 1Y | -25.5% | -3.4% | 6.1% |
Return vs Industry: 002898 underperformed the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 002898 underperformed the CN Market which returned 6.1% over the past year.
Price Volatility
| 002898 volatility | |
|---|---|
| 002898 Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 002898 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002898's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 483 | Nangui Cai | www.sailong.cn |
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd.
Sailong Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 002898 fundamental statistics | |
|---|---|
| Market cap | CN¥1.98b |
| Earnings (TTM) | CN¥1.52m |
| Revenue (TTM) | CN¥303.99m |
1,307x
P/E Ratio6.5x
P/S RatioIs 002898 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002898 income statement (TTM) | |
|---|---|
| Revenue | CN¥303.99m |
| Cost of Revenue | CN¥179.91m |
| Gross Profit | CN¥124.09m |
| Other Expenses | CN¥122.57m |
| Earnings | CN¥1.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0086 |
| Gross Margin | 40.82% |
| Net Profit Margin | 0.50% |
| Debt/Equity Ratio | 33.4% |
How did 002898 perform over the long term?
See historical performance and comparison